Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162695
Status:
TERMINATED
Last Update Posted:
2005-09-13
First Post:
2005-09-09
Brief Title:
Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood
Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Organization:
Gustave Roussy Cancer Campus Grand Paris
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objective of the study objectives was to explore survival advantage for an intensified chemotherapy strategy in a randomised trial
IVA ifosfamide vincristine actinomycin D or a 6 drug combination IVA carboplatin epirubicin etoposide both delivered over 27 weeks Cumulative dose m2 ifosfamide 54g both arms epirubicin 450 mg etoposide 1350 mg 6 drug Delivery of radiotherapy was determined according to site and or response to chemotherapy surgery
The study was powered to detect 10 difference in 3 year OS
IVA ifosfamide vincristine actinomycin D or a 6 drug combination IVA carboplatin epirubicin etoposide both delivered over 27 weeks Cumulative dose m2 ifosfamide 54g both arms epirubicin 450 mg etoposide 1350 mg 6 drug Delivery of radiotherapy was determined according to site and or response to chemotherapy surgery
The study was powered to detect 10 difference in 3 year OS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None